Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Zhejiang Hengkang Pharmaceutical","sponsor":"Zhejiang Hengkang Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zhejiang Hengkang Pharmaceutical Acquires Meiji Pharmaceutical (Shandong) to Enter the Field of Green Synthetic Biology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Zhejiang Hengkang Pharmaceutical

    Menu

    Zhejiang Hengkang Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Zhejiang Hengkang Pharmaceutical

              Contact Supplier
              • Deals
              Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
              Contact Supplier Contact Supplier
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zhejiang Hengkang Pharmaceutical Acquires Meiji Pharmaceutical (Shandong) to Enter the Field of Green Synthetic Biology

              Details:

              Through the acquisition, Hengkang entered the field of biosynthesis, improved the commercial production capacity of products in the field of biosynthesis, enriched its product pipeline by adding KD-370, a pentavalent vaccine, approved in Japan.

              Lead Product(s): KD-370

              Therapeutic Area: Infections and Infectious Diseases Product Name: KD-370

              Highest Development Status: Approved Product Type: Vaccine

              Recipient: Meiji Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition January 10, 2023

              Hengkang

              TIDES USA

              Booth # 802

              envelop Contact Supplier

              Hengkang
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY